Johnson & Johnson (JNJ)

About Johnson & Johnson

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.

As of November 3, 2026, Johnson & Johnson (JNJ) stock edged lower to $269.46, down 0.41% (-$1.10) versus the previous close. On the day, shares have traded between $267.74 and $270.56. That puts JNJ in the upper third of its 52-week range of $185.12 to $282.02. Johnson & Johnson operates in the pharmaceutical preparations space and carries a market capitalization of roughly $657.68 billion, with about 449.9K shares changing hands.

Latest JNJ news

• What Could Derail Bristol Myers Squibb Stock?trefis.com· Nov 3, 9:12 AM ET
• Is Intuitive Surgical Stock Worth More Than Its Competitors?trefis.com· Nov 3, 8:39 AM ET
• Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?Yahoo Finance· Nov 3, 8:00 AM ET
• Why Did Boston Scientific Stock Jump?trefis.com· Nov 3, 7:41 AM ET
• Kimberly-Clark Acquires Kenvue. Here’s What Investors Need to Know Ahead of Its Nov. 5 Earnings Report.fool.com· Nov 3, 1:20 AM ET
• 5 Top Stocks That Belong in a Retirement Portfoliotikr.com· Nov 2, 3:39 PM ET
• Betting On Drug Sales: Is Viatris Or Lilly The Better Way In?trefis.com· Nov 2, 3:21 PM ET
• Johnson & Johnson (JNJ) As Impella Data Fuels The Story, Is The Stock Fully Valued?Yahoo Finance· Nov 2, 2:09 PM ET

Source: Yahoo Finance RSS · Updated November 3, 2026

Want JNJ headlines, alerts and AI research in one place? Create a free account →

• $ABCL $MRNA $REGN $SLS $JNJ Now everyone is finding themselves chasing… All those sellers are now buying it up. Earnings coming up in a few days …November 9th Follow by 2 huge biotech conferences that they will be presenting at. November 9: Q3 earnings and pipeline update. Nov…

  @Stocktradesmoon· Nov 3, 9:41 AM ET· Bullish

• $SLS $RVMD $MRNA $JNJ Sellas GPS Regal Pivotal Registrational Phase 3 study Paradigm Shifting success = $120.00+ before BO because it’s the master key to 20+ other WT1 cancers. ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· Nov 3, 7:51 AM ET· Bullish

• JPMorgan🏁 $TRXB and said--We are initiating coverage of TRexBio (TRXB) with an OW rating and a Dec- 2027 PT of $20. [ $JNJ $LLY [ABBV SNY - REGN PFE CRVS QTTB MANE NKTR CLDX Dren Bio, ALYS Pharma, Legacy Healthcare, Reistone, Suzhou, EVMN KYMR BCRX ACRX]] JPMorgan went on to …

  @Quantumup· Nov 3, 7:18 AM ET

• $SLS $MRNA $RVMD $JNJ Sellas SSR in effect going in to Major Catalysts in Sellas Corporate history. 20,000 HTB shares available to short. 👇 ✌️🙏❤️‍🩹

  @SellasgpsCurativeBAT11· Nov 3, 7:17 AM ET· Bullish

• Off-exchange trading in $JNJ was above normal at about 1.3x. The full read shows the session-by-session dark pool share and which institutions are adding or cutting. The full dark-pool read, with the options side: https://globaltradersacademy.com/articles/dark-pool-activity-wh…

  @GlobalTradersAcademy· Nov 3, 2:06 AM ET

Source: Stocktwits. User posts are opinions, not verified facts. See what's trending →